Lofexidine May Effectively Mitigate Symptoms of Opioid Withdrawal Syndrome
Treatment with lofexidine may provide better control of the symptoms of opioid withdrawal syndrome compared with placebo.
Treatment with lofexidine may provide better control of the symptoms of opioid withdrawal syndrome compared with placebo.
Discontinuing short- or long-term use of esketamine nasal spray for treatment-resistant depression may not be associated with withdrawal symptoms.
Experts discuss how differentiation between the PTSD and TBI is important for the purposes of disability evaluation and treatment.
Virtual reality technology may be useful in such areas as exposure therapy and pain management.
The implementation of a standardized medication regimen for pain management in incoming psychiatric inpatients may be associated with a reduction in the number of pages related to pain complaints received by on-call residents.
The American Psychiatric Association’s president, Altha Stewart, MD, sat with Valerie Jarrett, JD, for a fireside chat focused on the Affordable Care Act.
A series of 3 articles published in the Lancet is dedicated to highlighting the nature of current postsurgical pain management practices, including the use of peri- and postoperative opioids, that are thought to play a part in driving the opioid crisis.
The Stopping the Transmission of Opioids to the Next Generation tool allows clinicians treating women of childbearing age with opioid use disorder to estimate risks associated with pregnancies in this patient population.
Dr Cosio presented results from a preliminary study examining the prevalence of mental health disorders in veterans with chronic pain.
The prevalence of opioid use disorder rose in women delivering at hospitals across 28 US states and the District of Columbia between 1999 and 2014, with quadrupling at the national level during this period.